-
XSpray Launches GMP Production Facility
9/1/2009
XSpray Microparticles AB, the Swedish life science technology company, today announced the launch of its new GMP production facility in Malmö, Sweden.
-
Groundbreaking Results In The RE-LY Trial - Novel Oral Direct Thrombin Inhibitor Dabigatran Etexilate Convincingly Beats Warfarin - Superior Stroke Reduction With Less Bleeding!
9/1/2009
Boehringer Ingelheim recently announced data from the landmark RE-LY study - the largest atrial fibrillation (AF) outcomes trial ever conducted (18,113 patients in 44 countries worldwide) - presented for the first time at the European Society of Cardiology Congress and published online in the New England Journal of Medicine.
-
Merck CEO Announces Structure And Global Leadership Team For New Merck
9/1/2009
Richard T. Clark, chairman, president and chief executive officer of Merck & Co., Inc. recently announced a new organizational structure and named top management and senior leaders for the new Merck effective upon completion of the merger of Merck & Co., Inc. and Schering-Plough Corporation. Mr. Clark was named CEO of the combined company when the merger agreement was signed in March.
-
FDA Commissioner Margaret Hamburg, Bestselling Author Jim Collins To Keynote RAPS Annual Conference In Philadelphia
8/31/2009
Professionals concerned with developing and bringing safe and effective drugs, medical devices, biotechnology and other healthcare products to the worldwide market will convene in Philadelphia next month for the Regulatory Affairs Professionals Society’s (RAPS) 2009 Annual Conference & Exhibition.
-
Thermo Fisher Scientific Introduces Stainless Steel Interior Models For Class II, Type A2 Biological Safety Cabinets
8/19/2009
Thermo Fisher Scientific Inc., the world leader in serving science, has introduced a one-piece stainless steel interior option for the Thermo Scientific 1300 Series A2 Biological Safety Cabinets.
-
Dual Devices By Pitt Researchers Harness Carbon Nanomaterials For Enhanced Drug Delivery Systems, Oxygen Sensors
8/18/2009
Two nanoscale devices recently reported by University of Pittsburgh researchers in two separate journals harness the potential of carbon nanomaterials to enhance technologies for drug or imaging agent delivery and energy storage systems, in one case, and, in the other, bolster the sensitivity of oxygen sensors essential in confined settings, from mines to spacecrafts.
-
CryoStim™ Cancer Treatment To Begin FDA Clinical Trials September 1, 2009
8/16/2009
Immunovative Therapies Ltd. has announced that its CryoStim™ experimental product has been cleared by the FDA to begin human clinical trials. Immunovative Therapies, Ltd. experimental products are based upon “Mirror Effect™” technology (patents issued and pending) which is designed to provide the same anti-tumor effect that has been proven to be curative in allogeneic bone marrow transplant (BMT) procedures without the lethal toxicity or need for a matched donor.
-
Biota Holdings Announces Successful Phase III Asian Clinical Trials Of Its Second Generation Flu Treatment
8/11/2009
Biota Holdings Limited (ASX: BTA) today announced successful results from the Asian Phase III clinical trials of CS-8958, its second generation influenza treatment.
-
Industry And FDA Leaders To Discuss The Evolving Science Of Cardiovascular Safety (CV) And Diabetic Drug Development
8/6/2009
The Drug Information Association (DIA) will host a two-day workshop on Cardiovascular Safety and Development of Type 2 Diabetes Mellitus Medications from September 23-24, 2009 in Washington, DC.
-
CCHRINT Announces FDA Reported Psychiatric Drug Side Effects Search Engine
8/6/2009
For the first time the side effects of psychiatric drugs that have been reported to the U.S. Food and Drug Administration (FDA) by doctors, pharmacists, other health care providers and consumers have been decrypted from the FDA's MedWatch reporting system and been made available to the public in an easy to search psychiatric drug side effects database and search engine.